Cannabis and Autoimmunity – The Neurologic Perspective: A Brief Review

Katz D1,2, Katz I1,2, Shoenfeld Y1,3*

1The Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, Israel
2Faculty of Medicine, The Hebrew University of Jerusalem, Israel
3Incumbent of the Laura Schwarz-kipp chair for research of autoimmune diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel

Introduction

The tale of Cannabis sativa is as old as time. Through its first days as an herbal remedy, ranging back to 4000 BC and to Emperor Shen Nung’s Rule (2700 BC), to cannabis low point of being banned internationally at 1925 to its recent re-emergence by prof. Mechoulam isolation of the Tetrahydrocannabinol (THC, 1963), Cannabis is slowly gaining its place in medicine1,2.

Cannabis sativa, also known as Marijuana has been called many names, yet the variety of names given to Cannabis does not encompass the vast medical opportunities that lie within the cannabis. As of now, 545 ingredients have been identified, of which over 100 classified as unique to Cannabis3. The two main and most researched active ingredients are - Tetrahydrocannabinol (THC) which holds a psychoactive properties and on the other hand, Cannabidiol (CBD) which is considered non psychoactive. The components are joined by the two main known endocannabinoids – Ananamide (AEA) and 2-Arachidonoylglycerol (2-AG) (also discovered by prof. Mechoulam and colleagues)4,5. The other half of the cannabinoid system (as we know thus far) comprises of CB1 and CB2 receptors, G-protein coupled receptors. The two receptors differ in distribution and function. While the major psychoactive effect of cannabis is attributed to the CB1 receptor and accordingly widely distributed in neurons, while the CB2 receptor has been linked to maintaining homeostasis and commonly appears in cells of the immune system6,7.

Cannabis and the Brain Immune System

It is well established that murine microglial cells express both CB1 and CB2 receptors, yet the pattern of receptors expression differs in location as well as in levels of expression. While CB1 receptor is consistently expressed in microglial cells in low levels, CB2 receptor is indetectable in resting state cells and highly expressed in activated microglia8,9. The pattern of expression and distribution of CB2 receptor in microglial cell suggest a role in microglial migration, CB2 receptor was found to be expressed heterogeneously throughout murine microglial cells with particularly high density at the leading edges of lamellipodia and microspkies (cellular protrusions that mediate cell migration). Moreover, 2-AG, AEA and abnormal-cannabidiol increase microglial cell migration10.
Another aspect of the endocannabinoid system effect on microglial cell is the attenuation of the immune response induced by LPS (Lipopolysaccharide) stimulation, AEA attenuates the immediate release of IL-6 and NO by microglial cell by induction of MPK-111.

A different mechanism of action is suggested by the inhibition of the IL-1 signaling pathway following administration of the synthetic cannabinoid R(+)-WIN 55,212-2. Appling R(+)-WIN 55,212-2 to astrocytoma cells prior stimulated by IL-1 resulted in dose dependent inhibition of ICAM-1 and VCAM-1 adhesion molecules induction, as well as IL-8 and NFκB. The effect aforementioned is independent from the cannabinoid receptors CB1 and CB2 as suggested by the lack of regulation of CB1 and CB2 antagonist on the immunomodulating effects mentioned above, implying that there is still much to learn in the field of Cannabis and immunomodulation.

Cannabis and the Blood-Brain-Barrier

The blood-brain-barrier (BBB) as well as the blood-spinal cord-barrier (BSCS) and their disturbance is often postulated as a possible mechanism of pathogenesis in neurological autoimmune disease. A possible link of pathogenesis has been suggested in Multiple Sclerosis13, Neuromyelitis Optica14, Guillain-Barré Syndrome15, Chronic Inflammatory Demyelinating Polyneuropathy16 and Antiphospholipid Syndrome with neurological involvement17.

In murine model of LPS induced vascular and inflammatory changes CBD counteracts the effect of LPS. Mice which received LPS+CBD showed no cerebral vasodilation, no leukocyte migration, reduced TNF-α and COX-2 levels compared to LPS treated mice and more over exhibited reduced dextran extravasation (dextran extravasation is used as a quantification instrument of BBB integrity)18.

Similar effect is obtained by administration of Anandamide to TMEV-infected endothelial brain cell. AEA inhibits VCAM-1 induction in vitro, and thus limit leukocyte migration through a transwell filter (coated with collagen type I and fibronectin) model of the BBB. Accordingly, in vivo experiment correlated the result of the in vitro experiments. AEA increased tone (by UCM-707, an AEA uptake inhibitor) inhibited VCAM-1 induced expression, as well as attenuated microglial cell activation19.

A role for CB2 receptor was also exemplified by in vivo murine model. Ex vivo CB2-activated leukocytes were injected to LPS treated mice resulting in adhesion reduction of up to 96% using GP1α (CB2 receptor agonist) in comparison with to non GP1α treated mice20.

The beneficial effect of cannabinoid also extends to human brain endothelial cells (BMVEC). Using human cells from HIV-1 CNS infected patients and from seronegative controls, a group of researches demonstrated enhanced CB2 receptor expression in HIV infected cells compared to controls. Further investigation of naive human BMVEC revealed that the increased expression of CB2 receptor can also be accomplished separately by IL-1β, TNF-α and LPS. Once induced and activated, CB2 receptor decreased leukocyte adhesion, prevented up regulation of adhesion molecules, promoted 2.2-2.7 increase in tight junction proteins (occludin and claudin-5) and significantly reduced BBB resistance drop induced by LPS21.

The coherence of the above mentioned experiments is also exemplified at the genetic level. Human BMVEC isolated from eleptogenic patients were activated using TNF-α to evaluate consequent gene expression. Out of 33 genes that were up regulated by TNF-α, 31 and 32 genes were suppressed using CB2 agonist O-1966 or JWH-133 respectively22.

Cannabinoids protective effect goes beyond the BBB and also extends to the BSCB. Pretreatment by JHW-015, a CB2 receptor agonist prevents down regulation of occludin and ZO-1 induced by spinal cord ischemia reperfusion injury (SCI) in murine in vivo model. Moreover, JWH-015 pretreatment reduces BBB leakage (measured by Evans blue) compared to SCI only group23.

Cannabis potential ability to protect BBB integrity is of possible great importance, not only in autoimmune neurologic disorders, but in a vast verity of neurological fields as in Alzheimer’s disease and ischemia injury.

Cannabis and Autoimmune Demyelinating Disease

Multiple Sclerosis (MS) is known as the hallmarks of neurological autoimmune disease with prevalence as high as 200:100,000 in some countries in northern Europe24.

MS Patients are characterized by high CSF levels of AEA compared to healthy control. In accordance high levels of AEA were also measured in autoimmune encephalomyelitis (EAE), a murine model of MS. Moreover, increased NAPE-PLD (part of AEA production) activity and reduced FAAH (degrades AEA) activity25. CB1 receptor deficient mice exhibit substantial neurodegeneration following EAE induction including higher prevalence of residual paresis and axonal pathology in relation to wild type mice26.

CBD treatment of TMEV infected mice induces a wide range of immunomodulatory outcomes. CBD reduce the infiltrate of immune cell to the brain parenchyma and decreased microglial activation. Moreover, CBD treatment has a long lasting effect, an 80 days follow up of the treatment group revealed restoration of both horizontal and vertical motor activities to that of the healthy mice and a correlating reduction in the expression of TNF-α and IL-β127.
MS is positively influenced by a variety of cannabinoids, both natural and synthetic, each demonstrating a different mechanism of action to our knowledge. Among the different cannabinoids we can find Cannabidiol which holds the ability to attenuate a range of neuronal apoptotic pathways, Cannabigerol Quinone which its application on murine neuronal culture results in inhibition of IL-1β, IL-6 and PGE2 release. Also Gp1a, a selective CB2 receptor agonist that modulates EAE development by reducing Th17 differentiation, and HU-446 and HU-465 (CBD derivatives) and many more which we won’t elaborate on.

There is scarce evidence regarding clinical use of Cannabis in MS patients. A recent Meta-analysis concluded that cannabinoids (nabilone and nabiximols) were associated with a greater average improvement in spasticity assessed by using numerical rating scale (mean difference, -0.76 [95% CI, -1.38 to -0.14]). Also, the average number of patients who reported an improvement on a global impression of change score was greater using nabiximols rather placebo (OR, 1.44 [95% CI, 1.07-1.94]). Notably, a new large multi centered blinded study was recently published, in which 489 MS patients participated and received either oral dronabinol (THC) or placebo. The study failed to prove the beneficial outcome of dronabinol use in two main outcomes (time to confirmed EDSS [Extended Disability Status Scale] score progression and change in MSIS-29 [Multiple Sclerosis Impact Scale-29] score). However, while taking into consideration the results of this trial, it is worth mentioning a possible weakness in the trial inclusion criteria. The disease progression in MS as measured by the EDSS scale is not linear, and progression through EDSS 4-5.5 is faster the in EDSS 6-6.6. hus making the EDSS 6+ patient’s population insensitive to treatment during the study period of time, leaving the question of Cannabis medical use in MS patients in need of further research. Currently, evidenced based recommendation published in 2014 by the American academy of neurology are: oral cannabis extracts (CBD/THC or CBD alone) are the

<table>
<thead>
<tr>
<th>System</th>
<th>Adverse Effect</th>
<th>Statistics*</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic</td>
<td>↓ hippocampus &amp; amygdala volumes</td>
<td>RR 1.13 (1.11-1.15)*</td>
<td>32,40-43</td>
</tr>
<tr>
<td></td>
<td>↑ Incidence of acute ischemic stroke</td>
<td>RR 2.26 (2.14 – 2.38)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age 15-54</td>
<td>RR 1.45 (1.42 – 1.54)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age 25 – 34</td>
<td>OR 3.68 (2.24-6.01)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age 45 - 54</td>
<td>OR 5.09 (4.10-6.32)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drowsiness</td>
<td>↓ 11% (% GCSE† points)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓Educational performance (adolescents)</td>
<td>Linear trend, t test t: -3.36***</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lower IQ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric</td>
<td>Psychosis</td>
<td>OR 1.41 (1.20–1.65)*</td>
<td>32,44,45</td>
</tr>
<tr>
<td></td>
<td>Schizophrenia</td>
<td>OR 1.9 (1.1–3.1)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
<td>OR 1.98 (0.73-5.35)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Depression</td>
<td>OR 1.49 (1.15–1.94)*</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Tachyarrhythmia</td>
<td>RR 1.5 (1.1–2.1)*</td>
<td>38,46,47</td>
</tr>
<tr>
<td></td>
<td>Palpitation</td>
<td>↓ 48% (↓ time to, during exercise)**</td>
<td></td>
</tr>
<tr>
<td>Pulmonary (cannabis smoking)</td>
<td>Chronic Bronchitis symptoms</td>
<td>25%-33% of smokers</td>
<td>46,48</td>
</tr>
<tr>
<td></td>
<td>↑health services for respiratory infections</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Nausea</td>
<td>OR 2.08 (1.63-2.65)*</td>
<td>32, 49,50</td>
</tr>
<tr>
<td></td>
<td>Diarrhea</td>
<td>OR 1.65 (1.04-2.62)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>OR 1.67 (1.13-2.47)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>General</td>
<td>Dry mouth</td>
<td>OR 3.50 (2.58-4.75)*</td>
<td>32, 38</td>
</tr>
<tr>
<td>Cannabis dependence</td>
<td>Adults, Adolescents</td>
<td>9%, 17% (percentage of users who will become addicted)</td>
<td>38, 51</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Insomnia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appetite disturbance</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Irritability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Maternal anemia</td>
<td>pOR 1.36 (1.1 – 1.69)*</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Decrease birth weight</td>
<td>pOR 1.77 (1.04 – 3.01)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↑Intensive care unit</td>
<td>pOR 2.02 (1.27 – 3.21)*</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: * Statistic differ is amount and substance used.  
* 95% CI  ** p<0.001  *** p value: 0.0009  
† RR : relative risk; OR : odds ratio; GCSE : General Certificate of Secondary Education; pOR : prevalence odds ratio; CI : confidence interval
only products with an A - effective rating, next in line is THC (dronabinol/nabilone) with B rating- probably effective.35.

Another demyelinating autoimmune disease that shows promise for cannabis treatment is Neuromyelitis Optica (NMO). Plasma levels of 2-AG were found to be elevated in NMO patients compared to healthy patients. Moreover, 2-AG levels were negatively correlated with pain sensitivity, while AEA correlated positively with pain sensitivity.36

Multiple Sclerosis and Neuromyelitis Optica are the milestones of medical cannabis implantation in neurologic autoimmune disease, yet only the foundation has been accomplished up to now and further clinical investigation is the core of establishing Cannabis Sativa and its products as a new therapeutic solution.

Cannabis Adverse Effects

Cannabis addiction is one of the main adverse effects of chronic cannabis use, though once considered as only "psychological addiction", recent evidence reveals a physiological ingredient to the addiction.37 Epidemiological studies indicate that about 9% of adult marijuana users will develop cannabis addiction, while adolescent’s percentages of addiction is as high as 17%.38

Another adverse effect of great importance lurking chronic cannabis users is the consequence anatomical changes, a 2013 meta-analysis concluded that chronic cannabis consumption results in reduction of hippocampal grey mater.39 Accordingly a new research conducted at 2015 demonstrated reduced hippocampus and amygdala volumes.40

Acute adverse effects (some may be found beneficial in some indications) include anxiety, dysphoria, psychosis/hallucinations, tachycardia, and stimulation of appetite.39 Another adverse effect of great importance lurking chronic cannabis users is the consequence anatomical changes, a 2013 meta-analysis concluded that chronic cannabis consumption results in reduction of hippocampal grey matter.39 Accordingly a new research conducted at 2015 demonstrated reduced hippocampus and amygdala volumes.40

Another adverse effect of great importance lurking chronic cannabis users is the consequence anatomical changes, a 2013 meta-analysis concluded that chronic cannabis consumption results in reduction of hippocampal grey matter.39 Accordingly a new research conducted at 2015 demonstrated reduced hippocampus and amygdala volumes.40

Conclusion

Nowadays Cannabis tends to be considered as a “buzz word”, with global recognition of the potential embodied in medical Cannabis, more and more countries legalize the use of medical cannabis, leaving many physicians overwhelmed due to the rapid changes. In this article we aimed to review the laboratory and clinical evidence regarding Medical Cannabis, more and more countries legalize the use of medical cannabis, leaving many physicians overwhelmed due to the rapid changes. In this article we aimed to review the laboratory and clinical evidence regarding Medical Cannabis and neurological autoimmune diseases.

Unfortunately, lack of clinical data prevents a definitive conclusion. Nonetheless, clinical trials conducted upon MS and NMO patients suggests a future role for medical cannabis in MS and NMO treatment by obtaining relief in patient symptoms. Yet, the trials aforementioned only paves the beginning, much research is yet to be done in order to evaluate the therapeutic effects of cannabis in treating autoimmune neurologic diseases versus.

Another promising aspect is cannabis protective effect on the BBB, having great potential not only in the field of autoimmunity but also in a variety of other pathologies with attributed BBB damage pathogenesis. The field of cannabis immunomodulation and BBB protection is an exciting new medical pathway, but only further research is to say what will be Cannabis sativa place in medical history.

Abbreviations

THC : Tetrahydrocannabinol; CBD : Cannabidiol; AEA : Ananamide; 2-AG : 2-Arachidonoylglycerol; LPS : Lipopolysaccharide; IL-6 : Interleukin 6; NO : Nitric oxide; MPK-1 : Mitogen-activated protein kinase 1; IL-1 : Interleukin 1; ICAM-1 : Intercellular Adhesion Molecule 1; VCAM-1 : vascular cell adhesion molecule 1; IL-8 : Interleukin 8; NFκB : Nuclear factor kappa-light-chain-enhancer of activated B cells; BBB : Blood - brain - barrier; BSCB : Blood – spinal cord – barrier; TNF-α : Tumor necrosis factor α; COX-2 : Cyclooxygenase-2; TMEV : Theiler’s Murine Encephalomyelitis Virus.

References


References


References


